Vitamin K2: The Missing Link in Bone and Heart Health

Vitamin K2: The Nutrient That Tells Calcium Where to Go

Most people associate calcium with bone health and leave it there. Far fewer have heard of the protein system that determines whether calcium ends up reinforcing the skeleton or calcifying arteries. Vitamin K2 sits at the centre of that system, and a growing body of evidence suggests it may be one of the most important and under-consumed nutrients in the modern Western diet.

K1 vs K2: Not the Same Thing

Vitamin K is commonly presented as a single nutrient, but the K vitamins are a family with meaningfully different properties. Vitamin K1 (phylloquinone), found in leafy green vegetables, is primarily taken up by the liver and used for blood coagulation — the function most people associate with vitamin K. Its half-life in circulation is short, measured in hours.

Vitamin K2 (menaquinone) is structurally different and behaves quite differently in the body. It is found in fermented foods and animal products, has a longer half-life, and reaches extrahepatic tissues including bone and the vascular wall. K2 exists in several sub-forms distinguished by the length of their side chain: MK-4 (menaquinone-4) is found in animal tissues and has a relatively short half-life; MK-7 (menaquinone-7) is the form produced by bacterial fermentation, found notably in natto (Japanese fermented soybean), and has a much longer half-life of approximately 72 hours, producing stable plasma concentrations from a once-daily dose.

The Calcium Paradox: Why Directing Calcium Matters

Calcium is essential for bone mineralisation, but unregulated calcium deposition is dangerous. Arterial calcification — the hardening of vessel walls — is a major risk factor for cardiovascular disease and is associated with significantly elevated mortality. The "calcium paradox" describes the observation that populations with high calcium intake can simultaneously experience bone loss and arterial calcification when calcium-directing proteins are not functioning adequately.

Two proteins are central to this system. Osteocalcin, produced by osteoblasts (bone-building cells), is required for the incorporation of calcium into hydroxyapatite crystals in bone matrix. Matrix Gla Protein (MGP), produced by vascular smooth muscle cells and chondrocytes, is the most potent known inhibitor of vascular calcification in humans.

Both osteocalcin and MGP are vitamin K-dependent proteins. They contain glutamate residues that must be carboxylated (converted to gamma-carboxyglutamate, or Gla) to function. This carboxylation reaction is catalysed by gamma-glutamyl carboxylase and requires vitamin K2 as a cofactor. Without adequate K2, osteocalcin and MGP remain uncarboxylated — inactive — and calcium is effectively left without a guide.

Uncarboxylated MGP (ucMGP) is now used as a biomarker of K2 insufficiency in research settings. Elevated ucMGP correlates with greater arterial stiffness and higher cardiovascular risk.

The Rotterdam Heart Study: Landmark Epidemiological Evidence

The most cited population study on K2 and cardiovascular health is the Rotterdam Heart Study, a large Dutch prospective cohort. A 2004 analysis by Geleijnse and colleagues followed 4,807 subjects over a mean of 7–10 years, examining dietary menaquinone intake and cardiovascular outcomes.

The findings were striking. Higher dietary MK intake was associated with a 41% reduction in coronary heart disease mortality, a 57% reduction in aortic calcification, and a 26% reduction in all-cause mortality. Crucially, dietary K1 intake showed no such associations. The analysis controlled for relevant confounders, and the dose-response relationship supported a genuine association rather than residual confounding.

Subsequent Dutch cohort studies have largely replicated these findings, consistently showing menaquinone — but not phylloquinone — associated with reduced arterial calcification and cardiovascular events.

Bone Health: The Osteocalcin Connection

The bone evidence is similarly compelling. Osteocalcin is the most abundant non-collagen protein in bone matrix, and its carboxylation status reflects K2 adequacy. In populations with very high MK-7 intake — notably Japan, where natto consumption is high — bone density is significantly higher than in other countries with comparable calcium intakes.

Randomised controlled trials in postmenopausal women have examined MK-7 supplementation and bone outcomes. A 2013 trial by Knapen and colleagues, published in Osteoporosis International, gave 180mcg MK-7 or placebo daily to 244 postmenopausal women for three years. The MK-7 group showed significantly reduced age-related decline in bone mineral density and bone strength at the lumbar spine and femoral neck. Crucially, the MK-7 group also showed significantly higher carboxylated osteocalcin — confirming target engagement.

A meta-analysis by Huang and colleagues (2015) examining K2 supplementation in randomised trials found significant reductions in vertebral fracture rates.

MK-4 vs MK-7: Which Form to Choose

MK-4 is the form used in Japanese pharmacological trials at very high doses (45mg three times daily) where it demonstrated fracture reduction in osteoporosis. At these doses, MK-4 acts partly through mechanisms beyond carboxylation. However, at supplemental doses available over the counter, MK-7 is pharmacokinetically superior: its longer half-life means a single daily dose maintains stable plasma and tissue concentrations throughout the day, whereas MK-4 peaks and clears relatively rapidly.

For general supplementation, MK-7 at 100–200mcg daily is the evidence-supported approach. The research base for MK-7 at 100mcg aligns with the Dutch cohort data and the Knapen fracture trial.

Safety and Drug Interactions

Vitamin K2 is fat-soluble and should be taken with a meal containing fat. It is well tolerated even at doses considerably above those tested in trials. The main clinical interaction is with warfarin: vitamin K (all forms) opposes warfarin's anticoagulant mechanism, and patients on warfarin should not supplement K2 without haematological supervision and INR monitoring. This is a firm contraindication, not a general caution.

For everyone else, K2 at supplemental doses is considered very safe.

Bottom Line

Vitamin K2 — particularly as MK-7 — is a genuinely important nutrient that operates at the intersection of bone health and cardiovascular protection via its role in activating calcium-directing proteins. The Rotterdam Heart Study and subsequent cohort data, combined with mechanistic understanding of osteocalcin and MGP carboxylation, make a compelling case. A daily dose of 100mcg MK-7 taken with a meal represents a well-supported, safe approach to ensuring this function is not chronically compromised.